| 产品描述： | Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM. |
| 靶点： |
EGFR:0.3 nM (IC50);ErbB2:16 nM (IC50);KDR:1.5 nM (IC50);Flt-4:8.7 nM (IC50);EGFR;VEGFR;FLT;EphrinReceptor |
| 体内研究： |
Tesevatinib (XL-647) shows potent and long-lived inhibition of the WT EGFR in vivo. Tesevatinib (XL-647) substantially inhibits the growth of H1975 xenograft tumors and reduces both tumor EGFR signaling and tumor vessel density |
| 参考文献： |
1. Gendreau SB, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res. 2007 Jun 15;13(12):3713-23. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.035 ml |
10.175 ml |
20.351 ml |
| 5 mM |
0.407 ml |
2.035 ml |
4.07 ml |
| 10 mM |
0.204 ml |
1.018 ml |
2.035 ml |
| 50 mM |
0.041 ml |
0.204 ml |
0.407 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京